Literature DB >> 15168161

Fatal exacerbation of paraneoplastic systemic sclerosis after neoadjuvant chemotherapy in a breast cancer patient.

Ruby Kochhar1, Jay N Umbreit.   

Abstract

Paraneoplastic systemic sclerosis (SSc) occurs in about 3%-7% of individuals with SSc. There are reports of accelerated SSc syndromes associated in particular with breast cancer. Further exacerbations of the rheumatic condition may be induced by treatment of the cancer. We report a 30-year-old African-American woman with a contiguous diagnosis of breast cancer and paraneoplastic SSc. She was treated with neoadjuvant chemotherapy and developed an accelerated SSc syndrome with pericarditis and cardiac tamponade, with lethal results. This case report stresses the need for control of the rheumatic condition prior to the initiation of antineoplastic therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168161     DOI: 10.1007/s10067-004-0875-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  Early immune events in scleroderma.

Authors:  A E Postlethwaite
Journal:  Rheum Dis Clin North Am       Date:  1990-02       Impact factor: 2.670

2.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

3.  Pseudoscleroderma associated with lung cancer: correlation of collagen type I and connective tissue growth factor gene expression.

Authors:  C Querfeld; S Sollberg; C Huerkamp; B Eckes; T Krieg
Journal:  Br J Dermatol       Date:  2000-06       Impact factor: 9.302

4.  Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.

Authors:  D W Puett; H A Fuchs
Journal:  J Rheumatol       Date:  1994-04       Impact factor: 4.666

Review 5.  [Systemic scleroderma and malignant diseases. A review of the literature].

Authors:  P Bielefeld
Journal:  Rev Med Interne       Date:  1991 Sep-Oct       Impact factor: 0.728

Review 6.  Immunologic aspects of scleroderma.

Authors:  B White
Journal:  Curr Opin Rheumatol       Date:  1995-11       Impact factor: 5.006

7.  Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis.

Authors:  T L Whiteside; Y Kumagai; A D Roumm; R Almendinger; G P Rodnan
Journal:  Arthritis Rheum       Date:  1983-07

8.  Incidence of lung cancer in systemic sclerosis.

Authors:  M Peters-Golden; R A Wise; M Hochberg; M B Stevens; F M Wigley
Journal:  J Rheumatol       Date:  1985-12       Impact factor: 4.666

9.  Effects of adriamycin, 4-hydroperoxycyclophosphamide and ASTA Z 7557 (INN mafosfamide) on the release of IL-2 and IL-1 in vitro.

Authors:  T A Abdul Hamied; D Parker; J L Turk
Journal:  Int J Immunopharmacol       Date:  1987

10.  Cancer and scleroderma.

Authors:  S C Duncan; R K Winkelmann
Journal:  Arch Dermatol       Date:  1979-08
View more
  1 in total

1.  Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study.

Authors:  Tim Y-T Lu; Catherine L Hill; Eliza K Pontifex; Peter J Roberts-Thomson
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.